{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(6)"],"submitter":["Mansour D"],"pubmed_abstract":["<h4>Objectives</h4>The primary objective was to assess the efficacy, cycle control and tolerability of a monophasic combined oral contraceptive (COC) containing nomegestrol acetate (NOMAC) and 17β-oestradiol (E2). Effects on acne were evaluated as a secondary objective. Results were compared to those of a COC containing drospirenone (DRSP) and ethinylestradiol (EE).<h4>Methods</h4>Women (aged 18-50 years) were randomised to receive NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=1591) or DRSP/EE (3 mg/30 μg) in a 21/7-day regimen (n=535) for 13 cycles.<h4>Results</h4>Estimated Pearl Indices for NOMAC/E2 and DRSP/EE were 0.38 and 0.81 in women aged≤35 years and 0.31 and 0.66 for all women (18-50 years), respectively. Scheduled withdrawal bleedings were shorter and lighter among users of N"],"journal":["The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception"],"pagination":["430-43"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3233274"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen."],"pmcid":["PMC3233274"],"pubmed_authors":["Mansour D","Taneepanichskul S","Sommer W","Weisberg E","Sundstrom-Poromaa I","Melis GB","Verhoeven C","Korver T"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen.","description":"<h4>Objectives</h4>The primary objective was to assess the efficacy, cycle control and tolerability of a monophasic combined oral contraceptive (COC) containing nomegestrol acetate (NOMAC) and 17β-oestradiol (E2). Effects on acne were evaluated as a secondary objective. Results were compared to those of a COC containing drospirenone (DRSP) and ethinylestradiol (EE).<h4>Methods</h4>Women (aged 18-50 years) were randomised to receive NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=1591) or DRSP/EE (3 mg/30 μg) in a 21/7-day regimen (n=535) for 13 cycles.<h4>Results</h4>Estimated Pearl Indices for NOMAC/E2 and DRSP/EE were 0.38 and 0.81 in women aged≤35 years and 0.31 and 0.66 for all women (18-50 years), respectively. Scheduled withdrawal bleedings were shorter and lighter among users of N","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Dec","modification":"2025-04-05T13:50:39.343Z","creation":"2019-03-27T00:46:49Z"},"accession":"S-EPMC3233274","cross_references":{"pubmed":["21995590"],"doi":["10.3109/13625187.2011.614029"]}}